-
Asthma solutions in demand
The one-time $100 million asthma-relief brand Primatene may make a comeback to the marketplace after a more than two-year hiatus. Primatene Mist had been withdrawn from the market in December 2011 when the agency removed all inhalers containing chlorofluorocarbons from the market.
-
GelStat finalizes deal for CBD Life Sciences, prepares to support GelStat Migraine relaunch and diet aid intro
PALM CITY, Fla. — GelStat Corp. on Wednesday announced that it has closed the acquisition of CBD Life Sciences.
Concurrent with the closing of the transaction, Larry Gershman has been appointed as CEO and chairman. Gerald Kieft, the company's prior CEO, will assume the position of CFO and be appointed to the board.